Rules
Aboutfair balancerisk disclosureindication on labelsubstantiationcomparativemisleading presentationname ingredientsubmissionpre approvalscientific exchangedisclosure
Naturepromotional
Document typeadvertisement
Risk info placementdistinct-part
Communication typeadvertisement
Regulatory classprescription-drug
Drug classprescription
Rx statusprescription
Advertising typeprescription-drug-advertisement
Populationhuman-use
Content triggerliterature-or-study-effectiveness-claim
Materialadvertisement
Content typeadvertisement
Active ingredient counttwo-or-more
Proprietary name basismixture-designation
Established name statusnone-for-mixture-designation
Drug classificationprescription
Labeling scenariosingle-proprietary-name-multiple-preparations-no-established-name
Prescription statusprescription-drug
Ad formattelevision
Intended specieshuman
Exemption statusnon-exempt
Approval pathwayaccelerated
21 of 251 rules
US-RISK-004·21 CFR 202.1(e)(1)(ii)AI-verified
DTC TV/radio major statement must be clear, conspicuous, and neutral
warningneeds human judgment
US-RISK-005·21 CFR 202.1(e)(1)(ii)(A)AI-verified
Major statement must use consumer-friendly, understandable language
warningneeds human judgment
US-RISK-006·21 CFR 202.1(e)(1)(ii)(B)AI-verified
Major statement audio must be at least as understandable as rest of the ad
warningneeds human judgment
US-RISK-009·21 CFR 202.1(e)(1)(ii)(C)(2)AI-verified
On-screen major statement text must remain readable for a sufficient duration
warningneeds human judgment
US-RISK-010·21 CFR 202.1(e)(1)(ii)(D)AI-verified
In TV-format DTC ads, major statement text must be easily readable
warningneeds human judgment
US-RISK-011·21 CFR 202.1(e)(1)(ii)(E)AI-verified
No audio/visual elements may interfere with comprehension of major statement
warningneeds human judgment
US-RISK-015·21 CFR 202.1(e)(3)(iii)AI-verified
Grouped side-effect terms allowed only if previously approved for that use
warningneeds human judgment
US-RISK-019·Section V, Recommendation 2 (exception)AI-verified
Disclose relevant risk information beyond the narrow scope of the request when material
warningneeds human judgment
US-RISK-020·Section V, Recommendation 6 (A copy of the FDA-required labeling bullet)Disputed
Accompany unsolicited-request response with FDA-required labeling, if any
warningcheckable
US-RISK-021·Section V, Recommendation 6 (A prominent statement notifying … bullet)Disputed
State prominently that FDA has not approved or cleared the discussed use
warningneeds human judgment
US-RISK-022·Section V, Recommendation 6 (A prominent statement providing … bullet)Disputed
Include prominent statement of all important safety information, including any boxed warning
warningneeds human judgment
US-RISK-023·Section VI, Recommendation 4AI-verified
Public response should include a mechanism to access current FDA-required labeling, if any
warningcheckable
US-RISK-024·Section V, Q2AI-verified
Disclose that the unapproved use is unapproved and unestablished
warningcheckable
US-RISK-025·Section V, Q2AI-verified
Disclose labeling limitations, restrictions, cautions, warnings, or precautions about the unapproved use
warningcheckable
US-RISK-026·Section V, Q2AI-verified
Disclose contraindications from the FDA-required labeling
warningcheckable
US-RISK-027·Section V, Q2AI-verified
Disclose serious, life-threatening, or fatal risks relevant to the unapproved use
warningneeds human judgment
US-RISK-028·Section V, Q2AI-verified
Disclose an applicable REMS and its goals
warningcheckable
US-RISK-029·Section III.A.4, Hierarchy of Risk InformationDisputed
FDA recommends stating the most important risk information first, especially in print
warningneeds human judgment
US-RISK-030·Section III.A.4, Hierarchy of Risk InformationAI-verified
Risk information should not be presented in only one location of the piece
warningneeds human judgment
US-RISK-033·Section III.B.2, The Nature of Benefit ClaimsAI-verified
Promotional pieces should reveal risks material to the specific benefit claims made
warningneeds human judgment
US-RISK-034·Section III.C.1, Location of Risk Information within a Part of the Promotional PieceDisputed
Risk information should not appear only on a brief summary page
warningneeds human judgment